Summanr Bone metastases from prostate carcinoma are predominantly osteoblastic. Recentlv. unrnary pyridinoline (Pyr) and deoxypyridinoline (Dpyr) Pvridinoline (Pyr). a cross-link within and between collagen molecules. contributes to the stability of collagen fibres. and is distributed mainly in bone. dentine and cartilage (Fujimoto et al.. 1978) . Deoxypyridinoline (Dpyr) is an analogue of Pyr and reportedly has a greater specificity for bone and dentine than does Pyr (Ogawa et al.. 1982 : Evre. 1987 
(3.1 ± .1 nmol mmol' creatinine. P <0.01). and also higher than that in the patients without metastasis (3.5 ± 1.9nmolmmol-' creatinine. P<0.05). There was no significant difference in Py-r and Dpyr levels between the control group and the patients without metastasis. These results suggest that bone resorption is also accelerated in prostate carcinoma patients with bone metastasis.
Pvridinoline (Pyr). a cross-link within and between collagen molecules. contributes to the stability of collagen fibres. and is distributed mainly in bone. dentine and cartilage (Fujimoto et al.. 1978) . Deoxypyridinoline (Dpyr) is an analogue of Pyr and reportedly has a greater specificity for bone and dentine than does Pyr (Ogawa et al.. 1982 : Evre. 1987 ). In the process of bone resorption. Pyr and Dpyr are excreted in the urine. and measurements of urinary. Pyr and Dpyr concentrations have been used to estimate the degree of bone resorption (Robins et al.. 1991) . Because Py-r and Dpyr have a high specificity for bone. are not affected by diet and are not internally metabolised. they mav be more useful markers of bone resorption than other substances investigated so far (Anon. 1992) . We have previously investigated the significance of urinarv Pyr and Dpyr as markers of bone resorption in healthy subjects (Ohishi et al.. 1993 ) and in patients with various bone metabolic diseases (Ohishi et al.. 1992 (Ohishi et al.. . 1994 .
It has been reported that urinary Pyr and Dpyr levels are elevated in patients with osteoclastic bone metastases (Paterson et al.. 1991 Urinar} Pyr and Dpyr levels were measured as described previously (Takahashi et al.. 1993) . Briefly. each urine sample was hydrolvsed with an equal volume of concentrated hydrochloric acid at 1 10°C for 20 h. The hydrolysate (0.25 ml) was mixed with 15 ml of distilled water and applied to an SPSephadex C25 column (0.8 x 1.0 cm). After than that in the control group (10.8 vs 3.1 nmol mmol-' creatinine P <0.01), and also higher than that in the patients without metastasis (3.5 nmol mmol-' creatinine, P<0.05) (Figure 2 ). There was no significant difference in Pyr or Dpyr levels between the control group and the patients without bone metastasis. AP levels showed no significant differences between any of these groups (Figure 3) .
On considering all the measured values, there was a significant correlation between Pyr and Dpyr (r = 0.833, P<0.001), between Pyr and AP (r = 0.40, P<0.05) and between Dpyr and AP (r=0.54, P<0.01).
D ion
Bone metastasis is a common event in the natural history of prostate carcinoma. Moreover, autopsy and roentgenological studies have revealed that bone metastases are of the pure osteoblastic variety in over 50% of cases (Elkin & Mueller, 1954; Jacobs, 1983 There were no significant inter-group differences. The lower bar is less than 0.
formation, and that few osteoclasts but many active osteoblasts surrounded by stromal cell proliferation are present in the bone metastases of patients with prostate carcinoma (Aoki et al., 1986) . Osteocalcin (bone gla protein, BGP) is regarded as a marker of osteogenesis or bone formation.
According to Shih et al. (1990) (Prockop, 1964) .
In this study. we demonstrated that the levels of both Pyr and Dpyr were increased significantly in the patients with bone metastasis compared with the control group. Thus, our results revealed that bone resorption was also accelerated in the bone metastases of patients with prostate carcinoma. despite the osteoblastic dominance associated with such metastases on histological and radiographic grounds. Moreover a significant increase in urinary Dpyr was observed in the patients with bone metastasis compared with the patients without bone metastasis. This finding may indicate that Dpyr is a more sensitive indicator of bone resorption than Pyr.
However, urinary Pyr and Dpyr measurements alone could not differentiate bone resorption originating from bone metastases from benign bone lesions (i.e. in the patient with bone metastases who has osteoporosis, the values of urinary Pyr and Dyr increase from the whole bone lesion. including benign bone lesion). In conclusion. urinary Pyr and Dpyr are useful diagnostic markers of bone metastasis although their relation to other bone resorptive diseases also needs to be examined.
